Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-826

No kidding, @yelrom. I was just thinking about how crazy it is to have these great results on CHF and CLBP, and not even have time right now to focus on moving those forward, simply because we have another, incredibly promising life saving treatment for ARDs that is taking priority. Imagine the envy of companies pinning their hopes on one treatment and one indication, when we have so many hot irons in the fire, we simply don't have time to run with them all at once. And it is time/people limitations here, not money, because getting investors to back development of these treatments will not be a problem. Now add to that the IP portfolio we are sitting on, and how many royalties they could generate when others using MSCs catch up to us and follow us on the path to commercialization. I am more confident than ever. The only uncertainty is time. But it will happen, and it will be